

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/NO2005/000465

International filing date: 19 December 2005 (19.12.2005)

Document type: Certified copy of priority document

Document details: Country/Office: NO  
Number: 20045612  
Filing date: 23 December 2004 (23.12.2004)

Date of receipt at the International Bureau: 23 January 2006 (23.01.2006)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

**BEST AVAILABLE COPY**



KONGERIKET NORGE  
The Kingdom of Norway

3

Bekreftelse på patentsøknad nr  
*Certification of patent application no*




20045612

▷ Det bekreftes herved at vedheftede dokument er nøyaktig utskrift/kopi av ovennevnte søknad, som opprinnelig inngitt 2004.12.23

▷ It is hereby certified that the annexed document is a true copy of the above-mentioned application, as originally filed on 2004.12.23

2006.01.04

  
Ellen B. Olsen  
Saksbehandler



72857301

## Søknad om patent

www.patentstyret.no



Ferdig utfylt skjema sendes til adressen nedenfor. Vennligst ikke heft sammen sidene.  
Vi ber om at blankettene utfylles *maskinelt* eller ved bruk av *blokkbokstaver*. Skjema for  
utfylling på datamaskin kan lastes ned fra [www.patentstyret.no](http://www.patentstyret.no).

2004-12-23

## ▼ Søker: Den som søker om patent blir også innehaver av eventuell rettighet. Må fylles ut!

Føretakets navn (fornavn hvis søker er person):

Jan

Etternavn (hvis søker er person):

Aasly

☐ Kryss av hvis søker tidligere har vært kunde hos Patentstyret.

Oppgi gjerne kundennummer:

Adresse:

Planetvegen 41

Postnummer:

7036

Poststed:

Trondheim

Land:

☒ Kryss av hvis flere søkere er angitt i  
medfølgende skjema eller på eget ark.☒ Kryss av hvis søker(ne) utfører  
20 årsverk eller mindre (se veiledning).

## ▼ Kontaktinfo: Hvem skal Patentstyret henvende seg til? Oppgi telefonnummer og eventuell referanse.

Fornavn til kontaktperson for fullmektig eller søker:

Bodil Merete

Etternavn:

Solli

☎ Telefon:

Referanse (maks. 30 tegn):  
polynukleotid

SØKNAD S. 1 AV 2

FLERE SØKERE

FLERE OPPFINNERE

PRIORITETER

VEILEDNING

## ▼ Fullmektig: Hvis du ikke har oppnevnt en fullmektig, kan du gå til neste punkt.

Føretakets navn (fornavn hvis fullmektig er person):

CURO AS

Etternavn (hvis fullmektig er person):

☐ Kryss av hvis fullmektig tidligere har vært kunde hos Patentstyret.

Oppgi gjerne kundennummer:

Adresse:

Postboks 38

Postnummer:

7231

Poststed:

Lundamo

Land:

## ▼ Oppfinner: Oppfinnere skal alltid oppgis, selv om oppfinner og søker er samme person.

Oppfinnerens fornavn:

Jan Aasly

Etternavn:

☐ Kryss av hvis oppfinner tidligere har vært kunde hos Patentstyret.

Oppgi gjerne kundennummer:

Adresse:

Planetvegen 41

Postnummer:

7036

Poststed:

Trondheim

Land:

☒ Kryss av hvis flere oppfinnere er angitt i medfølgende skjema eller på eget ark.

## ADRESSE

► Postboks 8160 Dep.  
Københavnsgaten 10  
0033 Oslo

## TELEFON

► 22 38 73 00  
TELEFAX  
► 22 38 73 01

## BANKIDR

► 8276.01.00192  
ORGANISASJONSNR.  
► 971526167 MVAPATENTSTYRET®  
Styret for det industrielle rettsvern

72857301

www.patentstyret.no



... søknad om patent

SØKNAD s. 2 av 2

▼ **Tittel:** Gi en kort beskrivelse eller tittel for oppfinnelsen (ikke over 250 tegn, inkludert mellomrom).

Tittel:  
Polynukleotid

▼ **PCT:** Fylls bare ut hvis denne søknaden er en videreføring av en tidligere innlevert internasjonal søknad (PCT).

Inngivelsesdato (åååå.mm.dd):

Søknadsnummer:

PCT-søknadens dato og nummer:

PCT

/

▼ **Prioritetskrav:** Hvis du ikke har søkt om denne oppfinnelsen tidligere i et annet land eller i Norge, kan du gå videre til neste punkt.

Prioritet kreves på grunnlag av tidligere innlevert søknad i Norge eller utlandet:

Inngivelsesdato (åååå.mm.dd):

Landkode:

Søknadsnummer:

Opplysninger om tidligere søknad. Ved flere krav skal tidligste prioritet angis her:

☐ Flere prioritetskrav er angitt i medfølgende skjema, eller på eget ark.

▼ **Biologisk materiale:** Fylls bare ut hvis oppfinnelsen omfatter biologisk materiale.

Søknaden omfatter biologisk materiale. Deponeringssted og nummer må oppgis:

(Deponeringssted og nummer: Beskriv gjerne eget ark):

☐ Prøve av materiale skal bare utleveres til en særlig sakkyndig.

▼ **Avdele/utskilt:** Hvis du ikke har søkt om patent i Norge tidligere, kan du gå videre til neste punkt.

Søknaden er avdele eller utskilt fra tidligere levert søknad i Norge:

Dato (åååå.mm.dd):

Søknadsnummer:

☐ Avdele søknad

Informasjon om opprinnelig

☐ Utskilt søknad

søknad/innsendt tilleggsmateriale

▼ **Annet:**

☒ Søknaden er også levert per telefaks.

Oppgi dato (åååå.mm.dd):

2004.12.23

☐ Jeg har fått utført forundersøkelse.

Oppgi nr (årstall - nummer - bokstav):

▼ **Vedlegg:** Angi hvilken dokumentasjon av oppfinnelsen du legger ved, samt andre vedlegg.

☒ Tegninger

Oppgi antall tegninger:

6

☒ Beskrivelse av oppfinnelsen

☒ Patentkrav

☐ Fullmaktsdokument(er)

☒ Sammandrag på norsk

☐ Overdragelsesdokument(er)

☐ Dokumentasjon av eventuelle prioritetskrav (prioritetsbevis)

☐ Erklæring om retten til oppfinnelsen

☐ Oversettelse av internasjonal søknad (kun hvis PCT-felt over er fylt ut)

☒ Annet: 5 sider sekvenslister

▼ **Dato/underskrift:** Sjekk at du har fylt ut punktene under «Søker», «Oppfinner» og «Vedlegg». Signer søknaden.

Sted og dato (blokkbokstaver):

Lundamo 23. desember 2004

Navn i blokkbokstaver:

Bodil Mcrete Sollie

Signatur:

Bodil Sollie

NB! Søknadsavgiften vil bli fakturert for alle søknader (dvs. at søknadsavgiften ikke skal følge søknaden).

Betallingsfrist er ca. 1 måned, se faktura.



**PATENTSTYRET®**  
Styret for det industrielle rettsvern

72857301

2004 -12- 23

Vedleggsskjema:

www.patentstyret.no

**Flere søkere**

Dette skjemaet benyttes som vedlegg til patentsøknaden for å oppgi flere søkere. NB! Gi hver søker et nummer. Personen oppgitt på søknadsskjemaet vil alltid bli registrert som nr. 01. Første angivelse på dette skjema vil være søker 02. Skjema for utfylling på datamaskin kan lastes ned fra [www.patentstyret.no](http://www.patentstyret.no).

Referanse: Gjenta referansen fra «kontaktinfo», eventuelt søkerens navn, som angitt på søknadsskjemaets første side. Må fylles ut!

Referanse:  
polynukleotid

▼ Søker nr. 2

Fornavn og mellomnavn:  
Zbigniew K.

Etternavn:  
Wszolek

☐ Søker har tidligere vært kunde hos Patentstyret.

Oppgi gjerne kundennummer:

Adresse:  
3868 Biggin Church Rd W.  
Jacksonville, FL 32224

Postnummer:

Poststed:

Land:  
USA

▼ Søker nr. 3

Fornavn og mellomnavn:  
Matthew J.

Etternavn:  
Farrar

☐ Søker har tidligere vært kunde hos Patentstyret.

Oppgi gjerne kundennummer:

Adresse:  
1858 Arden Way  
Jacksonville, FL 32250

Postnummer:

Poststed:

Land:

▼ Søker nr.

Fornavn og mellomnavn:

Etternavn:

☐ Søker har tidligere vært kunde hos Patentstyret.

Oppgi gjerne kundennummer:

Adresse:

Postnummer:

Poststed:

Land:

▼ Søker nr.

Fornavn og mellomnavn:

Etternavn:

☐ Søker har tidligere vært kunde hos Patentstyret.

Oppgi gjerne kundennummer:

Adresse:

Postnummer:

Poststed:

Land:

NB! Ved behov for mer plass benyttes flere skjema eller eget ark.

FLERE SØKERE



**PATENTSTYRET®**  
Styret for det industrielle rettsvern

72857301

Vedleggsskjema:

**Flere oppfinnere**[www.patentstyret.no](http://www.patentstyret.no)

Dette skjemaet benyttes som vedlegg til patentsøknaden for å oppgi flere oppfinnere. **NB! Gi hver oppfinner et nummer.** Personen oppgitt på søknadsskjemaet vil alltid bli registrert som nr. 01. Første angivelse på dette skjema vil være oppfinner 02. Skjema for utfylling på datamaskin kan lastes ned fra [www.patentstyret.no](http://www.patentstyret.no).

**Referanse:** Gjenta referansen fra kontaktinfo, eventuelt søkerens navn, som angitt på søknadsskjemaets første side. Må fylles ut!

Referanse:

polynukleotid

## ▼ Oppfinner nr. 2

Fornavn og mellomnavn:

Zbigniew K.

Etternavn:

Wszolek

☐ Oppfinner har tidligere vært kunde hos Patentstyret.

Oppgi gjerne kundennummer:

Adresse:

3868 Biggin Church Rd W.

Jacksonville, FL 32224

Postnummer:

Poststed:

Land:  
USA

## ▼ Oppfinner nr. 3

Fornavn og mellomnavn:

Matthew J.

Etternavn:

Farrar

☐ Oppfinner har tidligere vært kunde hos Patentstyret.

Oppgi gjerne kundennummer:

Adresse:

1858 Arden Way

Jacksonville, FL 32250

Postnummer:

Poststed:

Land:  
USA

## ▼ Oppfinner nr.:

Fornavn og mellomnavn:

Etternavn:

☐ Oppfinner har tidligere vært kunde hos Patentstyret.

Oppgi gjerne kundennummer:

Adresse:

Postnummer:

Poststed:

Land:

## ▼ Oppfinner nr.:

Fornavn og mellomnavn:

Etternavn:

☐ Oppfinner har tidligere vært kunde hos Patentstyret.

Oppgi gjerne kundennummer:

Adresse:

Postnummer:

Poststed:

Land:

NB! Ved behov for mer plass benyttes flere skjema eller eget ark.

FLERE OPPFINNERE



**PATENTSTYRET®**  
Styret for det industrielle rettsvern

72857301

2004 -12- 23

Referanse: Aasly

Fullmektig: CURO AS, Postboks 38, 7231 Lundamo

Tittel: Polynucleotide

72857301

1

Autosomal dominant parkinsonism linked to chromosome 12q12 (PARK8) has recently been attributed to pathogenic amino acid substitutions in leucine rich repeat kinase 2 (*LRRK2*). Addition linkage analysis and sequencing, within multiplex families, has confirmed the PARK8 assignment and identified a novel, heterozygous *LRRK2* mutation.

5 A referral sample of 248 patients with Parkinson's disease, consistent with autosomal dominant inheritance, was assessed and seven affected probands (2.8%) were found to carry the heterozygous 6055G>A transition (G2019S). By screening of three population-based series, six additional families carrying this mutation were identified. Within these

10 additional family members examined, twenty-two have a G2019S substitution, and seven had a diagnosis of Parkinson's disease. Disease penetrance is age-dependent, increasing from 17% at the age of 50 to 85% at the age of 70. The families originate from Norway, the US, Ireland, and Poland, but share an ancient ancestral haplotype, indicative of a common founder. In conclusion, our study demonstrates *LRRK2* G2019S accounts for

15 many families with autosomal dominant parkinsonism and suggests a substantial proportion of typical, late-onset Parkinson's disease has a genetic basis.

### Introduction

Parkinsonism (MIM168600) is a clinical syndrome characterized by bradykinesia, resting

20 tremor, muscle rigidity, and postural instability (Gelb et al. 1999). The most common cause of parkinsonism is Parkinson's disease (PD). Second to Alzheimer's disease, PD is the most common neurodegenerative disorder affecting >1% of the population over 55 years of age (de Rijk et al. 1995). Neuropathological findings in PD are loss of pigmented neurons in the brainstem, *substantia nigra* and *locus ceruleus*, with intracellular Lewy body

25 inclusions found within surviving neurons (Forno 1996).

Although PD is considered a sporadic disease, various hereditary forms of parkinsonism have been recognized (Vila and Przedborski 2004). A major breakthrough in recent years has been the mapping and cloning of a number of genes causing monogenic forms of parkinsonism. Genomic multiplication and missense mutations in the  $\alpha$ -synuclein

30 gene were initially identified in a small number of families with autosomal dominant parkinsonism (PARK1/4 [MIM 168601]) (Polymeropoulos et al. 1997; Kruger et al. 1998; Singleton et al. 2003; Chartier-Harlin et al. 2004; Farrer et al. 2004; Zarranz et al. 2004). Patients present with levodopa-responsive parkinsonism, however early-onset dementia is



72857301

2

frequent (Spira et al. 2001). Subsequently,  $\alpha$ -synuclein antibodies were found to robustly stain Lewy bodies and Lewy neurites in the *substantia nigra* in familial and sporadic PD (Spillantini et al. 1997) and common genetic variability in the  $\alpha$ -synuclein promoter has been implicated in sporadic PD (Pals et al. 2004).

5 Autosomal recessive mutations in three genes, *parkin*, *DJ-1* and *PINK1* have been linked with early-onset parkinsonism (<45 years at onset) (PARK2, PARK6 & PARK7 [MIM 602533, 602544 & 608309]) (Kitada et al. 1998; Bonifati et al. 2003; Valente et al. 2004). A large number of pathogenic mutations and rearrangements have been identified in the *parkin* gene reviewed by (Mata et al. 2004), but mutations in DJ-1 and PINK-1 are rare  
10 (unpublished data). Very recently, we identified pathogenic mutations in a novel gene, leucine-rich repeat kinase 2 (*LRRK2*) in six families with autosomal-dominant parkinsonism, linked to the PARK8 locus [MIM 607060]) (Zimprich et al. 2004a). Paisan-Ruiz and colleagues independently confirmed these findings in a British and Basque families (Paisan-Ruiz et al. 2004).

15 Herein, we describe a novel *LRRK2* mutation in thirteen families with diverse US and European origins, identified from a subset of 248 multiplex kindreds with dominantly inherited PD and three population-based series. Segregation analysis provides evidence for pathogenicity and an estimate of age-associated penetrance; haplotype analysis demonstrates the mutation originates from a common and ancient founder.

20

## Subjects and Methods

### Study subjects

The patients and controls were examined by neurologists specialized in movement disorders. A full history, including family history and neurological examination, was  
25 completed on each patient. Clinical diagnosis of PD required the presence of at least two of three cardinal signs (resting tremor, bradykinesia and rigidity), improvement from adequate dopaminergic therapy and the absence of atypical features or other causes of parkinsonism. All patients and controls are participating in genetic studies of PD and informed consent has been obtained from all participants. The Institutional Review Boards of the  
30 participating institutions have approved these studies.

72857301

3

*LRRK2 sequencing and mutation screening*

Blood samples were taken and genomic DNA was extracted using standard techniques. Six families (families 194, 281, 3081, 3082, 3083 and 3211) were known to have a positive LOD-score for microsatellite markers in the PARK8 locus (Zimprich et al. 2004b). Amplification of all 51 exons of the *LRRK2* gene was performed by polymerase chain reaction (PCR) in one patient from each of these six families. All PCRs were carried out for each primer set with 20-50 ng of template DNA in a total volume of 25 µl using a final reaction concentration of 200 µM dNTP, 1x PCR-Buffer (Qiagen), 1x Q-Solution (Qiagen), and 0.8 µM of each primer. One unit of Taq polymerase (Qiagen) was added to each reaction. Amplification was performed using a 57-52°C-touchdown protocol over 38 cycles. The primers used for PCR amplification of *LRRK2* exons and for sequencing are available on request.

The nucleotide sequences of all PCR products were determined by direct sequencing. Each PCR product was cleaned by using a Millipore PCR purification plate. Three microliters of purified PCR product was used per sequencing reaction with 1 µl of either the forward or reverse PCR primer and 1 µl of BigDye reaction mix (Applied Biosystems). Electrophoresis was performed under standard conditions on an ABI 3730 automated sequencer (Applied Biosystems). All sequences were obtained with both forward and reverse primers. Sequences were analyzed with SeqScape software version 2.1.1 (Applied Biosystems) and compared with published sequence of *LRRK2* (GenBank accession no. AY792511).

After identification of a heterozygous G2019S (G6055A) mutation in the proband of family 3215 (referred to as family 3211 in Zimprich et al, 2004b), we designed a probe employing TaqMan chemistry on an ABI7900 (Applied Biosystems) to screen for this mutation. First we examined 248 PD patients from families with a known family history, consistent with autosomal dominant transmission of the causative gene. Then 377 Norwegian, 271 Irish and 100 Polish PD patients were checked using this assay; 2260 control samples from similar populations were also included (1200 US American, 550 Norwegian, 330 Irish and 180 Polish subjects). Mutations were confirmed by direct sequencing of PCR products from *LRRK2* exon 41. Finally, all participating family members of *LRRK2* G2019 mutation carriers (affected and unaffected) were screened for the mutation.

72857301

4

*Genotyping of STR markers*

Fourteen microsatellite markers were genotyped in mutation carriers and all available family members, for linkage analyses and to determine whether there was a particular haplotype associated with the *LRRK2* mutation. Microsatellite markers were chosen to span the PARK8 region including D12S87, D12S1648, D12S2080, D12S2194, D12S1048, D12S1301 and D12S1701. *LRRK2* is located between D12S2194 and D12S1048. We also developed seven novel STR markers in this region (shown in table 1 below) by searching for repeat polymorphisms using RepeatMasker of *in silico* BAC sequence (UCSC Human Genome Browser Web site). The labeling of these novel markers reflects their physical position relative to the start codon of *LRRK2*.

Table 1. Novel chromosome 12 STR markers

Marker name	Primer sequence	Physical position (bp)
-31Kb	F: 5'-TTGCAGCTGTAAGGAATTTGGG-3'	38873779
	R: 5'-GCATTCTTCAGCCTGAGACCC-3'	
LRRK2_69Kb	F: 5'-TGAAGGACACTGAACAAGATGG-3'	38974140
	R: 5'-GCCATAGTCCTTCCATAGTTCC-3'	
LRRK2_84Kb	F: 5'-CGCAGCGAGCATTTGTACC-3'	38989214
	R: 5'-CTCGGAAAGTTTCCCAATTC-3'	
LRRK2_129Kb	F: 5'-CTGGTATTACCTCAACTGTGGCTC-3'	39034800
	R: 5'-ACTGGTATGTTTAAGCCTGGCAC-3'	
212Kb	F: 5'-AGCAGCAGAGAAGATTTCAATAAC-3'	39116816
	R: 5'-AATCATCTTTGAAAGAACCAGG-3'	
243Kb	F: 5'-TAAACGAAGCTCCCTCACTGTAAG-3'	39147728
	R: 5'-TCTTTGTAGCTGCGGTTGTTTC-3'	
378Kb	F: 5'-TCATGAAGATGTCTGTGATAGGGC-3'	39282976
	R: 5'-CTCTATTGTGAGCAAACCTGCATGG-3'	

One primer of each pair was labeled with a fluorescent tag. PCR reactions were carried out on 10-20 ng of DNA in a total volume of 15  $\mu$ l with final reaction concentrations of 150  $\mu$ M dNTP, 1x PCR-Buffer (Qiagen), 1x Q-Solution (Qiagen) and 0.6  $\mu$ M of each primer, with 1 unit of Taq Polymerase (Qiagen). Amplification was performed

72857301

5

using a 57-52°C-touchdown protocol over 38 cycles. The PCR product for each microsatellite was diluted by a factor of 10 to 100 with water. One microliter was then added to 10 µl of Hi-Di Formamide and Rox size standard. All samples were run on an ABI 3100 genetic analyzer, and results were analyzed using Genescan 3.7 and Genotyper 3.7 software (Applied Biosystems). Since population allele frequencies were not available from the CEPH database, these have been estimated by genotyping 95 unrelated subjects from the United States (shown in table 2 below).

**Table 2. Allele frequencies of STR markers**  
**Marker and allele (bp)      Frequency (%)**

<b>D12S87 (n = 92)</b>	
150	0.5
154	1.1
156	27.2
158	33.2
160	11.4
162	2.7
164	6.0
166	17.4
168	0.5
<b>D12S1648 (n = 91)</b>	
110	13.7
112	3.3
114	11.0
116	4.4
118	2.2
120	2.8
122	17.0
124	3.9
126	7.7
128	14.3
130	8.8
132	2.8
134	2.8
136	1.7
138	0.6
140	2.2
142	1.1
<b>D12S2080 (n = 93)</b>	
176	1.6
180	20.2
184	44.7
188	22.9
192	10.6

10 (continued)

72857301

6

Table 2 (continued)

Marker and allele (bp)	Frequency (%)
D12S2194 (n = 87)	
245	0.6
249	40.9
253	32.4
257	19.9
261	4.6
265	1.7
Marker and allele (bp)	Frequency (%)
-31Kb (n = 82)	
284	11.0
290	53.1
293	32.3
296	1.2
299	2.4
LRRK2_69Kb (n = 93)	
207	3.2
211	26.6
215	18.6
219	22.9
223	20.7
227	5.3
231	2.7
LRRK2_84Kb (n = 78)	
251	37.3
253	62.7
LRRK2_129Kb (n = 90)	
151	79.7
165	15.9
167	4.4
378Kb (n = 93)	
179	8.5
181	7.5
183	15.4
185	8.5
187	11.7
189	8.0
191	5.3
193	1.1
195	1.1
197	3.2
199	0.5
201	3.7
203	6.9

(continued)

72857301

7

Table 2 (continued)

Marker and allele (bp)	Frequency (%)
<b>378Kb (n = 93)</b>	
205	6.9
207	4.3
209	2.1
211	3.2
213	1.6
215	0.5
<b>212Kb (n = 72)</b>	
132	29.5
134	22.6
138	22.6
140	25.3
<b>243Kb (n = 89)</b>	
300	18.9
309	41.1
312	8.9
315	30.0
318	1.1
<b>D12S1048 (n = 89)</b>	
211	37.2
214	21.1
217	17.8
220	2.2
223	6.7
226	11.7
229	3.3
<b>D12S1301 (n = 93)</b>	
96	0.5
100	37.2
104	17.6
108	11.1
112	12.2
116	13.3
120	7.5
124	0.5
<b>D12S1701 (n = 93)</b>	
89	4.3
91	4.8
93	10.8
95	40.0
97	16.0
99	12.4
101	11.8
103	0.5

72857301

### Statistical Analysis

Multipoint nonparametric LOD scores for all families were calculated using GENEHUNTER-PLUS (Kong and Cox 1997). The frequency of the deleterious allele was set at 0.0001, and empirically determined allele frequencies were employed. The map positions for each marker were taken from Rutgers combined linkage-physical map version 1.0 (MAP-O-MAT web site). The three loci D12S2080, D12S2194 and D12S1301 are very tightly linked, with no observed recombinants in the database or within our genotyped families, and thus inter-marker distances were assigned as 0.01cM.

Chromosomal 12 haplotypes in the PARK8 region were established for those families in which chromosome phase for mutation-carrying individuals could be deduced, thereby determining which alleles co-segregated with the *LRRK2* G2019S mutation in each family. For those affected individuals in whom the associated allele for a marker could not be determined, both alleles are given.

The age-dependent penetrance was estimated as the probability of a gene carrier becoming affected, at a given age, within the 13 families. The number of affected mutation carriers, for each decade, was divided by the total number of affected individuals, plus the number of unaffected carriers within that range. For some affected family members no DNA was available and only historical data on the disease course was obtained. These individuals were excluded from penetrance calculations.

### Results

We identified 13 affected probands who carry a heterozygous G6055A mutation in exon 41 of the *LRRK2* gene. The mutation leads to a G2019S amino acid substitution of a highly conserved residue within the predicted activation loop of the MAPKKK domain (figure 1). After genotyping a total of 42 additional family members, 22 additional subjects were found to carry the mutation, seven with a diagnosis of PD (shown in table 3 below). One affected member of family P-089 did not carry the mutation and, for the purposes of this study, was considered a phenocopy and excluded from further analyses. Seven families originated from Norway, three were from the United States, two from Ireland, and one was from Poland. One family from the United States descended from Russian/Rumania, and another from Italy. For only one family (family 111), the ethnic origin was unknown. The *LRRK2* G2019S mutation segregates with disease in all kindreds, consistent with autosomal dominant transmission. To ensure patient confidentiality, simplified versions of the family

72857301

9

Table 3. Demographic and clinical information on 13 families with *LRRK2* G2019S.

	Family												PI
	P-063	P-089	P-104	P-241	P-369	P-394	E05-1	I210-1	I11-1	I120-1	PD66	3215-5	
Country of origin	Norway	Norway	Norway	Norway	Norway	Norway	Norway	US	US	US	Ireland	Ireland	Poland
No. of generations	3	4	2	3	2	3	4	2	2	3	2	2	1
Affected individuals	2	4	2	1	3	1	4	2	2	3	1	3	1
No. of typed individuals	1 (6)	2 (9)	1 (1)	1 (3)	2 (3)	1 (1)	3 (6)	1 (0)	2 (0)	3 (3)	1 (0)	2 (6)	1 (0)
affected (unaffected)													
No. of typed generations	2	3	2	2	1	2	3	1	1	2	1	1	1
Mean (range) age at onset	59	43	58	60	50	66	64	65	58	59	41	46	73
in years	(53-65)				(43-61)		(61-70)		(57-58)	(39-78)		(40-52)	
Maximum LOD-score		0.30	0	0	0.1	0	0.90	0	0.2	0.30	0	0.30	0



72857301

10

pedigrees are presented in figure 2. There was no evidence of the mutation in 2260 control samples.

Age at onset of clinical symptoms was quite variable, even within the same family. Family 1120, a family from the United States, had both the earliest and latest age at onset for a patient. The youngest affected subject had an onset at 39 years, whereas the oldest carrier presented with initial symptoms at 78 years. Where recorded, most *LRRK2* G2019S carriers have late-onset disease (>50 years at onset). The mean age at onset of affected mutation carriers was 56.8 years (range 39-78 years, n=19). Unaffected carriers have a mean age of 53.9 years (range 26-74 years, n=14). The penetrance of the mutation was found to be highly age-dependent, increasing from 17% at the age of 50 to 85% at the age of 70 (figure 4).

Evidence for linkage to the *PARK8* locus was found across families, with a combined maximum multipoint LOD score of 2.10 [for all 14 markers], corresponding to a P value of 0.001. As only a defined chromosomal region was investigated, rather than a genome-wide search, this LOD score exceeds that required for significance,  $P=0.01$  (Lander and Kruglyak 1995). A positive LOD score was found in all families where more than one affected subject was genotyped (table 3).

All affected members from the different families, except the individual in family P-089 who did not carry the mutation, appear to share a common haplotype on chromosome 12 in the area of the *LRRK2* gene (figure 3). Haplotypes can be established with certainty in nine of the families, and all mutation carriers in these families share alleles for four microsatellite markers closely linked to the *LRRK2* gene. These markers are *LRRK2* 84Kb, 129Kb, 212Kb and 243Kb. For the remaining families, the number of available samples from relatives was not sufficient to determine phase. However, the genotypes in these cases are consistent with a common *LRRK2* G2019S allele. *LRRK2*\_84Kb is located in intron 29 and *LRRK2*\_129Kb is located in intron 44 of the *LRRK2* gene, whereas the two other shared markers are positioned 3' of the gene. Using the physical position of the shared and non-shared markers, the size of the shared haplotype is between 158 kb and 309 kb.

## Discussion

We have identified a novel *LRRK2* mutation, G2019S, which co-segregates with autosomal dominant parkinsonism in 13 kindreds originating from several European populations. Positive LOD scores were obtained in multiplex families, and combined they

provide significant support for the PARK8 locus. *LRRK2* G2019S mutation was absent in a large number of control subjects, and of similar ethnicity. The number of families linked to *LRRK2* in this and previous studies now explains the majority of genetically defined autosomal dominant parkinsonism.

5           The mean age at onset of affected *LRRK2* G2019S carriers was 56.8 years, and comparable to that of patients in other families linked to PARK8 (Funayama et al. 2002; Paisan-Ruiz et al. 2004; Zimprich et al. 2004a). The majority of patients present with late-onset disease, indistinguishable from typical idiopathic PD. Disease penetrance is age-dependent, and increases in a linear fashion from 17% at the age of 50 to 85% at the age of  
10 70. Age is the single most consistent risk factor for development of PD and other neurodegenerative disorders (Lang and Lozano 1998), and an important risk factor in *LRRK2* associated parkinsonism. Interestingly, age at onset was variable in this study, both within and between different families, suggesting other susceptibility factors, environmental or genetic, may influence the phenotype.

15           Although our findings clearly indicate that *LRRK2* mutations account for a substantial proportion of familial late-onset parkinsonism, historically, cross-sectional twin studies have not supported a genetic etiology for late-onset PD (Tanner et al. 1999; Wirdefeldt et al. 2004). The age-associated penetrance of *LRRK2* mutations provides some explanation as even large and well designed twin studies are underpowered to detect  
20 incompletely penetrant mutations (Simon et al. 2002). *LRRK2* mutations were also found in apparently sporadic PD patients; three of the patients in this study did not have any known affected first- or second-degree relatives. However, a caveat of age-dependent penetrance is that carriers may die of other diseases, before manifesting or being diagnosed with PD. Thus, it seems difficult to separate sporadic and familial PD, or to hypothesize  
25 environmental causes to be more important in one group and genetic causes more prominent in the other. In light of these results, a family history of parkinsonism, previously considered an exclusion criterion for a diagnosis of PD, must be reconsidered (Hughes et al. 1992).

*LRRK2* is a member of the recently defined ROCO protein family (Bosgraaf and  
30 Van Haastert 2003). In human, mouse and rat, members of the ROCO protein family have five conserved domains (figure 1). The kinase domain belongs to the MAPKKK subfamily of kinases. The active sites of all kinases are located in a cleft between an N-terminal and a C-terminal lobe, typically covered by an 'activation loop', in an inactive conformation. The activation loop must undergo crucial structural changes to allow access to peptide

72857301

12

substrates and to orientate key catalytic amino acids (Huse and Kuriyan 2002). In different kinases, the activation loop starts and ends with the conserved residues asp-phc-gly (DFG) and ala-pro-glu (APE), respectively (Dibb et al. 2004). Of note, the *LRRK2* G2019S substitution changes a highly conserved amino acid at the start of this loop (figure 5). In a German family we previously described, an I2020T mutation is located in an adjacent codon (Zimprich et al. 2004a). In other kinases, oncogenic mutations in residues within the activation loop of the kinase domain have an activating effect (Davies et al. 2002), thus we postulate *LRRK2* G2019S and I2020T mutations may have an activating effect on its kinase activity.

The age of an allele may be estimated from the genetic variation among different copies (intra-allelic variation), or from its frequency (Slatkin and Rannala 2000). However, the local recombination rate on chromosome 12q12 is unknown, as is the frequency of the G2019S mutation in the general population. Nevertheless, at centromeres there is generally a dearth in recombination; indeed no crossovers have been observed between *LRRK2* flanking markers D12S2194 and D12S1048 in our studies, or within CEPH families (MAP-O-MAT web site). The physical size of the shared haplotype is also small, between 158 kb and 309 kb, and the allele is widespread in families from several European populations. Hence, the mutation is likely to be ancient and may be relatively common in specific populations. These data suggest a substantial proportion of late-onset PD will have a genetic basis.

#### Electronic-Database Information

The physical position of markers is from NCBI build 34. Accession numbers and URLs for data presented herein are as follows:

Online Mendelian Inheritance in Man (OMIM), <http://www.ncbi.nlm.nih.gov/Omim/>

MAP-O-MAT, <http://compugen.rutgers.edu/mapomat>

RepeatMasker, <http://www.repeatmasker.org/>

#### References

Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC,

- Brice A, Mecco G, van Duijn CM, Oostra BA, Heutink P (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. *Science* 299:256-9
- Bosgraaf L, Van Haastert PJ (2003) Roc, a Ras/GTPase domain in complex proteins. *Biochim Biophys Acta* 1643:5-10
- 5 Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Leveque C, Larvor L, Andrieux J, Hulihan M, Waucquier N, Defebvre L, Amouyel P, Farrer M, Destee A (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. *Lancet* 364:1167-9
- 10 Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, et al. (2002) Mutations of the BRAF gene in human cancer. *Nature* 417:949-54
- de Rijk MC, Breteler MM, Graveland GA, Ott A, Grobbee DE, van der Meche FG, Hofman A (1995) Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. *Neurology* 45:2143-6
- 15 Dibb NJ, Dilworth SM, Mol CD (2004) Switching on kinases: oncogenic activation of BRAF and the PDGFR family. *Nat Rev Cancer* 4:718-27
- Farrer M, Kachergus J, Forno L, Lincoln S, Wang DS, Hulihan M, Maraganore D, Gwinn-Hardy K, Wszolek Z, Dickson D, Langston JW (2004) Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. *Ann Neurol* 55:174-9
- 20 Forno LS (1996) Neuropathology of Parkinson's disease. *J Neuropathol Exp Neurol* 55:259-72
- Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F (2002) A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. *Ann Neurol* 51:296-301
- 25 Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. *Arch Neurol* 56:33-9
- Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. *J Neurol Neurosurg Psychiatry* 55:181-4
- 30 Huse M, Kuriyan J (2002) The conformational plasticity of protein kinases. *Cell* 109:275-82
- Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. *Nature* 392:605-8

72857301

14

- Kong A, Cox NJ (1997) Allele-sharing models: LOD scores and accurate linkage tests. *Am J Hum Genet* 61:1179-88
- Krugger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O (1998) Ala30Pro mutation in the gene encoding alpha-synuclein  
5 in Parkinson's disease. *Nat Genet* 18:106-8
- Lander E, Kruglyak L (1995) Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. *Nat Genet* 11:241-7
- Lang AE, Lozano AM (1998) Parkinson's disease. First of two parts. *N Engl J Med* 339:1044-53
- 10 Mata IF, Lockhart PJ, Farrer MJ (2004) Parkin genetics: one model for Parkinson's disease. *Hum Mol Genet* 13 Spec No 1:R127-33
- Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, de Munain AL, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Marti-Masso JF, Perez-Tur J, Wood NW, Singleton AB  
15 (2004) Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease. *Neuron* 44:595-600
- Pals P, Lincoln S, Manning J, Heckman M, Skipper L, Hulihan M, Van den Broeck M, De Pooter T, Cras P, Crook J, Van Broeckhoven C, Farrer MJ (2004) alpha-Synuclein promoter confers susceptibility to Parkinson's disease. *Ann Neurol* 56:591-5
- 20 Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. *Science* 276:2045-7
- 25 Simon DK, Lin MT, Pascual-Leone A (2002) "Nature versus nurture" and incompletely penetrant mutations. *J Neurol Neurosurg Psychiatry* 72:686-9
- Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muentner M, Baptista M, Miller D, Blancato J, Hardy J,  
30 Gwinn-Hardy K (2003) alpha-Synuclein locus triplication causes Parkinson's disease. *Science* 302:841
- Slatkin M, Rannala B (2000) Estimating allele age. *Annu Rev Genomics Hum Genet* 1:225-49

72857301

15

- Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. *Nature* 388:839-40
- Spira PJ, Sharpe DM, Halliday G, Cavanagh J, Nicholson GA (2001) Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. *Ann Neurol* 49:313-9
- 5 Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, Langston JW (1999) Parkinson disease in twins: an etiologic study. *Jama* 281:341-6
- Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, Gonzalez-
- 10 Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. *Science* 304:1158-60
- Vila M, Przedborski S (2004) Genetic clues to the pathogenesis of Parkinson's disease. *Nat Med* 10 Suppl:S58-62
- 15 Wirdefeldt K, Gatz M, Schalling M, Pedersen NL (2004) No evidence for heritability of Parkinson disease in Swedish twins. *Neurology* 63:305-11
- Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, de Yebenes JG (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. *Ann Neurol* 55:164-73
- 20 Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T (2004a) Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology. *Neuron* 44:601-7
- 25 Zimprich A, Muller-Myhsok B, Farrer M, Leitner P, Sharma M, Hulihan M, Lockhart P, Strongosky A, Kachergus J, Calne DB, Stoessl J, Uitti RJ, Pfeiffer RF, Trenkwalder C, Homann N, Ott E, Wenzel K, Asmus F, Hardy J, Wszolek Z, Gasser T (2004b) The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. *Am J Hum Genet* 74:11-9
- 30



72857301

16

**Patent claims**

1. A polynucleotide consisting of the base sequence of SEQ ID NO: 2, or a complementary strand thereof, wherein the X is one of the group being defined by the bases A, C or T
- 5 2. A polynucleotide according to claim 1, wherein the polynucleotide is at the least a part of a gene.
3. A peptid consisting of the base sequence of SEQ ID NO:1, wherein the x is not glycine.
- 10 4. A recombinant vector comprising a polynucleotid according to claim 1.
5. A DNA probe specific for the polynucleotide of claim 1, wherein it contains more than 10 consecutive nucleotides from the nucleotide, or the complementary strand.
- 15 6. A method of proving parkinsonism inheritance, by screening a sample of material taken from the subject of interest, with a probe according to claim 5.
7. DNA primer specific for the polynucleotide of claim 1, wherein it contains more than 10 consecutive nucleotides from the nucleotide, or the complementary strand.
- 20 8. Use of a polynucleotide according to claim 1, or a vector according to claim 4, to transfect an organism.
- 25 9. Use according to claim 8, wherein the organism is a mammal.



30

72857301

2004-12- 23

1/5

## SEQUENCE LISTING

LOCUS AY792511 7584 bp mRNA linear PRI 15-NOV-2004

5 DEFINITION Homo sapiens leucine-rich repeat kinase 2 (LRRK2) mRNA, complete cds.

ACCESSION AY792511

VERSION AY792511.1 GI:55740397

KEYWORDS

10 SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 7584)

15 AUTHORS Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., Stoessl, J., Pfeiffer, R. F., Patenge, N., Carballo, J., Vieregge, P., Asmus, F., Mueller-Mysok, B., Meitinger, T., Strom, T. M., Wszolek, Z. and Gasser, T.

20 TITLE Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology

JOURNAL Neuron 44 (4), 601-607 (2004)

PUBMED 15541309

REFERENCE 2 (bases 1 to 7584)

25 AUTHORS Zimprich, A., Biskup, S. and Strom, T. M.

TITLE Direct Submission

JOURNAL Submitted (22-OCT-2004) Institute of Human Genetics, Technical University and GSF Research Center, Ingolstaedter Landstr. 1, Muenchen/Neuherberg 85764, Germany

30 FEATURES Location/Qualifiers

source 1..7584

/organism="Homo sapiens"

/mol\_type="mRNA"

/db\_xref="taxon:9606"

35 /chromosome="12"

/map="12q12"

/tissue\_type="brain"

/dev\_stage="adult"

gene 1..7584

40 /gene="LRRK2"

CDS 1..7584

/gene="LRRK2"

/codon\_start=1

/product="leucine-rich repeat kinase 2"

45 /protein\_id="AAV63975.1"

/db\_xref="GI:55740398"

## SEQUENCE NO 1

50 /translation="MASGSCQGCEEDEETLKKLIVRLNNVQEGKQIETLVQILEDLLV



72857301

2/5

FTYSEHASKLFLQGKNIHVPLLVLD SYMRVASVQQVGVWSLLCKLIEVCPGTMQSLMGP  
QDVGNDWEVLGVHQLKMLTVHNASVNL SVIGLKTLDLLTSGKITLLTDEESDIF  
MLIFDAMHSFPANDEVQKLGCKALHVL FERVSEEQLTEFVENKDYMILL SASTNFKDE  
BEIVLHVLHCLHSLAIPCNNVEVLM SGNVRCYNIVVEAMKAFPMSEIRJQEVSCCLLHR  
5 LTLGNFFNILVLNEVHEFVVKAVQQYPENAAQLISALSCLALLTETIFLNQDLEEKNE  
NQENDDEGEEDKLFWLEACYKALTWHRKNKHVQEAACWALNNLLMYQNSLHEKIGDED  
GHFPAHREVMLSMLMHSSSKEVFQASANALSTLLEQNVNFRKILLSKGIHLNVLELMQ  
KHHSPEVAESGCKMLNHLFEGSNTSLDIMA AVVPKILTVMKRHETSLPVQLEALRAI  
LHFIVPGMPESREDTEFHKLNMVKKQCFKNDIHKLVLAALNRFIGNPGIQKCGLKV  
10 ISSIVHFPDALEMLSLEGAMDSVLHTLQMYPDDQEIQCLGLSLUGYLITKKNVFIQTG  
HLLAKILVSSLYRFKDVAEIQTKGFQTLAILKLSASF SKLLVHHSFDLVIFHOMSSN  
IMEQKDQQFLNLCKCFKAVAMDDYLKNVMLERACDQNSIMVECLLLL GADANQAKE  
GSSLICQVCEKESSPKLVELLLNSGSREQDVRKALTISIGK GDSQIISLLRLALDV  
ANNSICLGGFCIGKVEPSWLGPLFPDKTSNLRKQTNIASTLARMVIRYQMKSAVEGT  
15 ASGSDGNFSEDLVSKFDEWTFPDSSMDSVFAQSDDL DSEGSEGSFLVKKKSNSISVG  
EFYRDAVLQRCSPNLQRHSNSLGPFDHEDLLKRKRKILSSD DLSRSSKLQSHMRHSD  
SISSLASEREYITSLDLSANELRDIDALSQKCCISVHLEHLEKLELHQNALTSFPQQL  
CETLKSILTHLDLHSNKFTSFPSYLLKMSCIANLDVSRNDIGPSVVLDP TVKCPTLKQF  
NLSYNQLSFVPENLTDVVEKLEQLLEGNKISGICSPRLKELKILNLSKNHISSLSE  
20 NFLEACPKEVESFSARMNFLAAMPFLPPSMTILKLSQNKFSCEPAEILNPHLRSLDMS  
SNDIQYLPGPAHWKSLNRLRELLFSHNQISILDSEKAYLWSRVEKLHL SHNKLKEIPP  
BIGCLENLTSLDVSYNLELRSFPNEMGKLSKIWDLPDELHLNFD FKHIGCKAKDIIR  
FLQQLKKA VPYNRMKLMIVGNTGSGKTTLQQLMKT KKSDDLGMQSATV GIDVKDWPI  
QIRDKRKRDLVLNVWDFAGREEFYSTHPHMTQRALYLA VYDLSKGQAEVDAMKPWLF  
25 NIKARASSSPVJLVGTHLDVSDEKQRKACMSKITKELLNKR GFPAIRDYHFVNATEES  
DALAKLRKTINESLNFKIRDQLVVGQLIPDCYVELEKILSERKNVPIEFVDRKR  
LLQLVRENQLQDENELPHAVHFLNESGVLLHFQDPALQLSDLVFVEPKWLCKIMAQI  
LTVKVEGCPKHPKGHSRRDVEKFLSKKRKF PKNYMSQYFKLLEKFQIALPIGEYLL  
VPSSLSDHPRVIELPHCENSEIIRLYEMPYFPMGFWSRLINRLLEISPYMLSGRERA  
30 LRPNRMVWRQGIYLNWSPEAYCLVGSEVLDNHPESFLKITVPSCRKGCILLGQVVDHI  
DSLMEWFPGLEIDICGEGETLLKKWALYSFNDGEEHQKILLDDL MKKAEEGDLLVN  
PDQPRLTIPISQIAPDLILADLPRNIMLNNDLEFEQAPEFLLGDG SFGSVYRAAYEG  
EEVAVKIFNKHTSLRLRQELVVLCHLHHPSLISLLAAGIRPRMLVMELASKGSLDRL  
LQQDKASLTRTLQHRIALHVADGLRYLHSAMIYRDLKPHNVLLFTLYPNAALIAKIA  
35 DYXIAQYCCRMGIKTSEGTGPFRAPEVARGNVIYNQQADVYSFGLLLYDILT TGGRIV  
EGLKFPNEFDELEIQGKLDPDVKEYGCAPWPMVEKLIKQCLKENPQERPTSAQVEDIL  
NSAELVCLTRRILLPKNVIVECMVATHNSRNASIWLGCGHTDRGQLSFLDLNTEGYT  
SEEVADSRILCLALVHLPVEKESWIVSGTQSGTLLVINTEDGKKRHTLEKMTDSVTCL  
YCNSFSKQSKQKNFLLVGTADGKLAIFEDKTVKLKGAAPL KILNIGNVSTPLMCLSES  
40 TNSTERNVMWGGCGTKIFSFSNDFJTQKLIETRTSQLFSYAAFSDSNIITVVVDALY  
IAKQNSPVVEVWDKKTEKLCGLIDCVHFLREVMVKENKESKHKMSYSGRVKTLCLQKN  
TALWIGTGGGHILLDLSTRRLIRVIYNFCNSVRVMMTAQLGSLKNVMLVLGYNRKNT  
EGTQKQKEIQSCLTVWDINLPHEVQNLEKHIEVRKELAEKMRRTSVE"  
misc\_difference 149  
45 /gene="LRRK2"  
/note="compared to genome assembly"  
/replace="g"  
variation 3364  
/gene="LRRK2"  
50 /note="I1122V"  
/phenotype="PARK8"  
/replace="g"  
variation 4321  
/gene="LRRK2"

72857301

3/5

/note="R1441C"  
 /phenotype="PARK8"  
 /replace="t"  
 variation 5096  
 5 /gene="LRRK2"  
 /note="Y1699C"  
 /phenotype="PARK8"  
 /replace="g"  
 variation 5457  
 10 /gene="LRRK2"  
 /note="nonsynonymous SNP"  
 /replace="t"  
 variation 6055  
 15 /gene="LRRK2"  
 /note="G2019S"  
 /phenotype="PARK8"  
 /replace="g"

## SEQUENCE NO 2

20 1 atggctagtg gcagctgtca ggggtgcgaa gaggacgagg aaactctgaa gaagttgata  
 61 gtcaggctga acaatgtcca ggaaggaaaa cagatagaaa cgctgggtcca aatcctggag  
 121 gatctgtggt tgttcaogta ctccgagcac gcctccaagt tatttcaagg caaaaatatac  
 181 catgtgcctc tgttgatcgt ctggactcc tatatgagag tcgagagtgt gcagcagggtg  
 241 ggttggtcac ttctgtgcaa attaatagaa gtctgtccag gtacaatgca aagcttaatg  
 25 301 ggacccacagg atgttggaag tgattgggaa gtccttggtg taccacaatt gattcttaaa  
 361 atgctaacag ttcataatgc cagtgtaaac ttgtcagtga ttggactgaa gaccttagat  
 421 ctctcctaa ctccaggtaa aatcaccttg ctgatactgg atgaagaaag tgatatttc  
 481 atgttaattt ttgatgccat gcactcattt ccagccaatg atgaagcca gaaacttgga  
 541 tgcaaaagctt tacatgtgct gtttgagaga gtctcagagg agcaactgac tgaatttgtt  
 30 601 gagaacaaag attatatgat attgttaagt gcgtcaacaa attttaaaga tgaagaggaa  
 661 attgtgcttc atgtgctgca ttgttiacat tccctagcca ttccctgcaa taatgtggaa  
 721 gtccctatga gtggcaatgt caggtgttat aatattgttg tggaagctat gaaagcattc  
 781 cctatgagtg aaagaattca agaagtgagt tgcgtttgc tccataggct tacattaggt  
 841 aatttltca atatcctggt attaaacgaa gtccatgagt ttgtgtgaa agctgtgcag  
 35 901 cagtaccag agaatgcagc attgcagatc tcagcgtca gctgtttggc cctcctcact  
 961 gagactattt tcttaaatca agatttagag gaaaagaatg agaataaaga gaatgatgat  
 1021 gagggggaag aagataaatt gttttggctg gaagcctgtt acaaagcatt aacgtggcat  
 1081 agaaagaaca agcacgtgca ggaggccgca tgcgtggcac taataatct ccttatgtac  
 1141 caaaacagtt tacatgagaa gattggagat gaagatggcc atttccagc tcataggga  
 40 1201 gtgatgctct ccatgctgat gcattcttca tcaaaggaag tttccagge atctgcgaat  
 1261 gcattgtcaa ctctcttaga acaaaatgtt aatttcagaa aaatactgtt atcaaaagga  
 1321 atacacctga atgttttga gttaatgcag aagcatatac attctcctga agtggctgaa  
 1381 agtggctgta aaatgctaaa tcattctttt gaaggaagca acacttcctt ggatataatg  
 1441 gcagcagtggt tccccaaaat actaacagtt atgaaacgtc atgagacatc attaccagtg  
 45 1501 cagctggagg cgcttcgagc tattttacat ttatagtgc ctggcatgcc agaagaatcc  
 1561 agggaggata cagaatttca tcataagcta aatatggta aaaaacagtg ttcaagaat  
 1621 gatattcaca aactggctct agcagctttg aacaggttca ttggaaatcc tgggattcag  
 1681 aaatgtggat taaaagtaat ttctctatt gtacatttc ctgatgcatt agagatgta  
 1741 tccctggaag gtgctatgga ttcatgtctt cacacactgc agatgtaicc agatgacca  
 50 1801 gaaattcagt gtctgggttt aagcttata ggatactga ttacaaagaa gaatgtgttc

72857301

4/5

1861 ataggaactg gacatctgct ggcaaaaatt ctggttcca gcttataccg atttaaggat  
1921 gttgctgaaa tacagactaa aggatttcag acaatcttag caatcctcaa attgtcagca  
1981 tctttttcta agctgctggt gcatcattca ttgacttag taatattcca tcaaatgtct  
2041 tccaatatca tggacaacaaa ggatcaacag ttctaaacc tctgttgcaa gtgttttgca  
5 2101 aaagtagcta tggatgatta cttaaaaaat gtgatgctag agagagcgtg tgatcagaat  
2161 aacagcatca tgggtgaatg cttgcttcta tgggagcag atgccaatca agcaaaggag  
2221 ggatcttctt taatttgtca ggtatgtgag aaagagagca gtcccaaat gggtggaactc  
2281 ttactgaata gtggatctcg tgaacaagat gtacgaaaag cgttgacgat aagcattggg  
2341 aaaggtgaca gccagatcat cagcttgcct ttaaggaggc tggccctgga tgtggccaac  
10 2401 aatagcattt gccctggagg atttgtata ggaaaagtgg aaccttctg gcttggctct  
2461 ttattccag ataagacttc taatttaagg aaacaacaa atatagcafc tacactagca  
2521 agaattggtga tcagatatca galgaaaagt gctgtggaag aaggaacagc ctcaggcagc  
2581 gatggaaatt ttctgaaga tgtgctgctt aaattgatg aatggacctt tattctgac  
2641 tctctatgg acagtgtgtt tgcctaaagt gatgacctgg atagtgaagg aagtgaaggc  
15 2701 tcatttctg tgaaaaagaa atctaatica attagttag gagaattta ccgagatgcc  
2761 gtattacagc gttgctcacc aaatttgcaa agacattcca attccttggg gccattttt  
2821 gatcatgaag atttactgaa gcgaaaaaga aaaatactat ctccagatga ttactcagg  
2881 tatcaaaaac tcaatccca tatgaggcat tcagacagca ttcttctct ggttctgag  
2941 agagaatata ttacatcact agaccttca gcaaatgaac taagagatat tgatgccta  
20 3001 agccagaaat gctgtataag tgttcattg gagcatctg aaaagctgga gcttcaccag  
3061 aatgcactca cgagcttcc acaacagcta tgtgaaact tgaagagtt gacacattg  
3121 gacttgaca gtaataaatt tacatcattt ccttcttatt tgtgaaat gattgtatt  
3181 gctaatctg atgtctctg aaatgacatt ggacctcag tggtttga tctacagt  
3241 aaatgcca cctgaaaca gttaacctg tcatataacc agctgtctt tctacctgag  
25 3301 aacctcactg atgtgtaga gaaactggag cagctcatt tagaaggaaa taaaatatca  
3361 gggatatgct ccccttgag actgaaggaa ctgaagatt taaacctag taagaaccac  
3421 attcatccc tatcagagaa ctttctgag gctgtccta aagtggagag ttacagtgcc  
3481 agaatgaatt ttctgctgc tatgccttc tgcctcctt ctatgacaat cctaaaatta  
3541 tctcagaaca aatttctg tattccagaa gcaattttaa atctccaca cttgcggtct  
30 3601 itagatatga gcagcaatga tattcagtac ctaccaggc ccgcacactg gaaatcttg  
3661 aacttaaggg aactcttatt tagccataat cagatcagca tcttggacti gattgaaaaa  
3721 gcatatttat ggtctagagt agagaaactg catcttctc acaataaact gaaagagatt  
3781 cctcctgaga ttggtgtct tgaaaactg acatctctg atgtcagta caactggaa  
3841 ctaagatcct ttccaatga aatggggaaa ttaagcaaaa tatgggact tctttggat  
35 3901 gaactgcac ttaacttga tttaaacat ataggatga aagccaaaga catcataagg  
3961 ttcttcaac agcgaltaaa aaaggctgtg cctataacc gaatgaaact tatgattgtg  
4021 ggaaatactg ggagtgtgaa aaccacctta ttgcagcaat taatgaaac caagaaatca  
4081 gatcttggaa tgcgaagtgc cacagtggc atagatgtga aagactggcc tatccaaata  
4141 agagacaaaa gaaagagaga tctcgtcta aatgtgtggg attttgcagg tctgaggaa  
40 4201 ttctatagta ctcatccca ttatgacg cagcgagcat tttacctgc tgtctatgac  
4261 ctacgaagg gacaggctga agttgatgcc atgaagcct ggctctcaa tataaaggct  
4321 cgcgttctt ctccctgt gattctggt ggacacatt tggatgttc tgatgagaag  
4381 caacgcaag cctgcatgag taaatcacc aaggaactcc tgaataagcg aggttccct  
4441 gccatagag attaccatt tgtgaatgcc accgaggaat ctgatgttt ggcaaacit  
45 4501 cggaaaacca tcaaaacga gagcctaat tcaagatcc gagatcagct tgtgttgga  
4561 cagctgattc cagactgcta tgtagaactt gaaaaaatca ttatcgga gcgtaaaaat  
4621 gtgccaatg aatttccgt aattgaccgg aaacgattat tacaactagt gagagaaaat  
4681 cagctgcagt tagatgaaa tgaactcct cagcagttc acttctaaa tgaatcagga  
4741 gtccttctc atttcaaga ccagcactg cagttaagt acttgtact tgtggaaccc  
50 4801 aagtggcctt gtaaaatcat ggcacagatt ttacagtga aagtggaagg ttgtccaaa

72857301

5/5

4861 caccctaagg gcattatttc gcgtagagat gtggaaaat ttctttcaaa aaaaaggaaa  
4921 ttccaaaga actacatgtc acagtatttt aagctcctag aaaaattcca gattgctttg  
4981 ccaataggag aagaatattt gctggttcca agcagtttgt ctgaccacag gcctgtgata  
5041 gagcttcccc attgtgagaa ctctgaaatt atcatccgac tatatgaaat gccttatttt  
5 5101 ccaatgggat ttgggtcaag attaatcaat cgattacttg agatttcacc ttacatgctt  
5161 tcaggggagag aacgagcact tcgcccacac agaattgtat ggcgacaagg cattacttia  
5221 aattggcttc ctgaagctta ttgtctggta ggatctgaag tcttagacaa tcatccagag  
5281 agtttcttaa aaattacagt tcttcttgt agaaaaggct gtattctttt gggccaagtt  
5341 gtggaccaca ttgattctct catggaagaa tggtttctg gtttctgga gattgatatt  
10 5401 tgggtggaag gagaactct gtgaagaaa tgggcattat atagttttaa tgatggcgaa  
5461 gaacatcaaa aaatcttact tgatgacttg atgaagaaag cagagggaagg agatctctta  
5521 gtaaatccag atcaaccaag gctaccatt ccaatatctc agattgcccc tgacttgatt  
5581 ttggctgacc tgcctagaaa taitatgttg aataatgatg agttggaatt tgaacaagct  
5641 ccagagtttc tcttaggtga tggcagtttt ggatcagttt accgagcagc ctatgaagga  
15 5701 gaagaagtgg ctgtgaagat tttaataaaa catacatcac tcaggctgtt aagacaagag  
5761 ctgtggtgc ttgccacct ccaccaccoc agtttgatat ctltgtggc agctgggatt  
5821 cgtccccgga tgttggatg ggagttagcc tccaagggtt ctttgatcg cctgcttcag  
5881 caggacaaag ccagctcac tagaaccta cagcacagga ttgcactcca cgtagctgat  
5941 ggtttgagat acctccactc agccatgatt atataccgag acctgaaacc ccacaatgtg  
20 6001 ctgctttica cactgtatcc caatgtgcc atcattgcaa agattgtgta ctacXgcatt  
6061 gctcagtact gctgtagaat ggggataaaa acatcagagg gcacaccagg gtttctgca  
6121 cctgaagtig ccagaggaaa tctcatttat aaccaacagg ctgatgttta ttcatgtgt  
6181 ttactactct atgacatttt gacaactgga ggtagaatag tagagggttt gaagttcca  
6241 aatgagtttg atgaattaga aatacaagga aaattacctg atccagttaa agaattatgt  
25 6301 tgtccccat ggcctatggt tgagaaatta attaaacagt gtttgaaga aaatcctcaa  
6361 gaaaggccca ctctgccca ggtcttgac atttgaatt cagctgaatt agtctgtctg  
6421 acgagacgca ttattacc taaaacgta attgtgaat gcatggtgc tacacatcac  
6481 aacagcagga atgcaagcat ttggctgggc tgtgggcaca ccgacagagg acagcttca  
6541 ttcttgact taaatactga aggatacact tctgaggaag ttgtgatag tagaatattg  
30 6601 tgcttagcct tgggtcatct tctgttgaa aaggaaagct ggattgtgtc tgggacacag  
6661 tctgtactc tctgttcat caataccgaa gatgggaaa agagacatac cctagaaaag  
6721 atgactgatt ctgtcacttg ttgtattgc aattccttt ccaagcaaag caaacaaaa  
6781 aatttcttt tggttggaac cgctgatggc aagttagcaa ttttgaaga taagactgtt  
6841 aagcttaag gagctgtctc ttgaagata ctaatatag gaaatgtcag tactccattg  
35 6901 atgtgttga gtgaatccac aaatcaacg gaaagaaatg taatgtgggg aggatgtggc  
6961 acaaagattt tctcttctc taatgatttc accattcaga aactattga gacaagaaca  
7021 agccaactgt ttcttatgc agcttctagt gattccaaca tcataacagt ggtggtagac  
7081 actgtctct atattgctaa gcaaaatagc cctgttgtgg aagtgtggga taagaaaact  
7141 gaaaaactct gggactaat agactgcctg cacttttaa gggaggtaat ggtaaaagaa  
40 7201 aacaaggaa caaacacaa aatgtcttat tctgggagag tgaaaaccct ctgccttcag  
7261 aagaacactg ctctttgat aggaactgga ggaggccata ttctactct ggtctttca  
7321 actcgtcagc ttatcgtgt aattacaac ttgttaatt cggtcagagt catgatgaca  
7381 gcacagctag gaagccttaa aaatgtcatg ctggtattgg gctacaaccg gaaaaatac  
7441 gaaggtacac aaaagcagaa agagatacaa tctgtttga ccgtttggga catcaatct  
45 7501 ccacatgaag tgcaaaatt agaaaaacac attgaagtga gaaaagaatt agctgaaaa  
7561 atgagacgaa catctgttga gtaa

//



72857301

**Abstract:**

A polynucleotide consisting of the base sequence of SEQ ID  
NO: 2, or a complementary strand thereof, wherein the X is  
one of the group being defined by the bases A, C or T







Figure 1. Schematic drawing of *LRRK2* with predicted protein domains

(LRR – leucine rich repeat, Roc – Ras in complex proteins, COR – domain C-terminal of Roc, MAPKKK – mitogen-activated protein kinase kinase kinase, WD40 – WD40 repeats). The human *LRRK2* protein sequence in the region of the G2019S mutation is aligned with orthologs from rat (XP\_235581), mouse (AAH34074), frog (AAH76853), and puffer fish (CAG05593). The chromatogram shows the 6055G>A transition (G2019S)




72857301


Family P-241




Family P-104



Family P-089




Family P-063




Family I210




Family F05



Family P-394



Family P-369



72857301





Figure 2. Pedigrees of families with *LRRK2* G2019S

Blackened symbols denote affected family members with parkinsonism. An asterisk denotes genotyped individual, with "m" for mutation carriers and "wt" for wild-type *LRRK2*. To protect confidentiality, the genotypes and genders of some unaffected individuals are not shown.





72857301

Marker	Family proband												Country of origin
	P-063	P-089	P-104	P-241	P-369	P-394	F05	1210	1120	111	3215	PD66	1P
D12S87	160	160	164	164	166	156	166	156/158	164	160	158	156/166	166/158
D12S1648	120	120	122	122	122	110	110	122/124	110	110	110	120/134	128/130
D12S2080	188	188	188	188	188	188	188	184/192	188	180	184	188/192	184/188
D12S2194	261	261	261	261	261	261	261	253/261	257	257	253	245/249	249/261
-31Kb	290	290	290	290	290	290	290	290/290	290	290	290	290/293	284/290
LRRK2_69Kb	223	223	223	223	223	223	223	223/223	223	223	223	215/215	211/219
LRRK2_84Kb	223	223	223	223	223	223	223	223/223	223	223	223	223/223	223/223
LRRK2_129Kb	188	188	188	188	188	188	188	188/188	188	188	188	188/188	188/188
212Kb	188	188	188	188	188	188	188	188/188	188	188	188	188/188	188/188
243Kb	188	188	188	188	188	188	188	188/188	188	188	188	188/188	188/188
378Kb	188	188	188	188	188	188	188	188/188	188	188	188	188/188	188/188
D12S1048	214	214	214	214	214	214	214	214/214	214	214	214	214/214	211/226
D12S1301	112	116	120	120	116	116	116	108/116	100	120	116	100/116	100/100
D12S1701	95	97	91	91	95	95/97	97	95/101	92	91/95	95	97/101	91/97
Country of origin													
Norway													
United States													
Ireland													
Poland													

Figure 3. Chromosome 12q12 STR markers on the disease haplotype (PARK8).

Genotypes for probands from 13 families with *LRRK2* G2019S are shown; those shared are highlighted in grey.

72857301




Figure 4. Probability of becoming affected by parkinsonism, in *LRRK2*G2019S carriers, as a function of age.



72857301

LRRK2	DYGIAQ-----YCCRMGIKTSEGTGGERAPE
LRRK1	DYGISR-----QSFHEGALGVEGTPGYQAPE
MATK	DFGLAK-----AERKGLDSSRLPVKWTAPE
PDGFRA	DFGLARDIMHDSNYVSKGSTFLPVKWMMAPE
MAP3K10	DFGLAR-----EWHKTTKMSAAGTYAMMAPE
DAPK1	DFGN-----EFKNIFGTPEEYAPE
BRAF	DFGLATVKSRWSGSHQFEQLSGSILWMAPE

Figure 5. Aligned amino acid sequences of the activation loop of different human kinases.

In most kinases, the activation loop starts and ends with the conserved residues DFG and APE, respectively. In *LRRK2* and *LRRK1* phenylalanine is changed to tyrosine, an amino acid with a similar structure. (*LRRK2* – leucine-rich repeat kinase 2, *LRRK1* – leucine-rich repeat kinase 1, *MATK* – megakaryocyte-associated tyrosine kinase, *PDGFRA* – platelet-derived growth factor receptor alpha, *MAP3K10* – mitogen-activated protein kinase kinase kinase 10, *DAPK1* – death-associated protein kinase 1, *BRAF* – v-raf murine sarcoma viral oncogene homolog B1)



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ ~~COLOR~~ OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ ~~LINES~~ OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**